- |||||||||| lysergic acid diethylamide (LSD) / Mindmed, University Hospital Basel
Review, Journal: H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids? (Pubmed Central) - Jan 1, 2022
We have performed a systematic review with the primary aim of exploring published literature where H NMR analysed psychedelic substances including psilocin, lysergic acid diethylamide (LSD), LSD derivatives, N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and bufotenin...Additionally, potential future directions for psychedelic research were identified as real-time NMR, in vivo H nuclear magnetic resonance spectroscopy (MRS) and H NMR studies of the gut microbiome. Further psychedelic studies need to be conducted that incorporate the use of H NMR spectroscopy in the analysis of metabolites both in the peripheral biofluids and in vivo to determine whether it will be an effective future approach for clinical and naturalistic research.
- |||||||||| lysergic acid diethylamide (LSD) / Mindmed, University Hospital Basel
PK/PD data, Retrospective data, Journal: Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. (Pubmed Central) - Nov 7, 2021
Lysergic acid diethylamide (LSD) is a classic psychedelic substance that is used recreationally and investigated in psychiatric research...These findings indicate that genetic polymorphisms of CYP2D6 significantly influence the pharmacokinetic and subjective effects of LSD. Given the potential therapeutic use of psychedelics, including LSD, the role of pharmacogenetic tests prior to LSD-assisted psychotherapy needs to be further investigated.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion: L-Ket: Effect of Ketanserin After LSD Administration (clinicaltrials.gov) - Oct 21, 2021
P1, N=24, Completed,
Given the potential therapeutic use of psychedelics, including LSD, the role of pharmacogenetic tests prior to LSD-assisted psychotherapy needs to be further investigated. Recruiting --> Completed
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion date, Trial initiation date, Trial primary completion date: LSD-Bio: LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects (clinicaltrials.gov) - Sep 8, 2021
P1, N=20, Not yet recruiting,
Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2022 Trial completion date: Jun 2022 --> Mar 2023 | Initiation date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2022 --> Mar 2023
- |||||||||| lysergic acid diethylamide (LSD) / Mindmed, University Hospital Basel
Journal: Role of the 5-HT Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin. (Pubmed Central) - Jul 31, 2021
The psychedelic lysergic acid diethylamide (LSD) has experienced a revival in research, including clinical trials that evaluate LSD-assisted psychotherapy...In contrast, LSD-induced oxytocin release may depend on 5-HT receptor stimulation, which is consistent with the psychedelic effect of LSD. Further studies are needed to investigate whether LSD may also enhance empathy and potentially produce therapeutic effects in patients who have deficits in empathy and impairments in social functioning.
- |||||||||| lysergic acid diethylamide (LSD) / Mindmed, University Hospital Basel
Clinical, PK/PD data, Journal: Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants. (Pubmed Central) - Jul 17, 2021
The 10 µg dose of LSD significantly increased ratings of "under the influence" and "good drug effect" compared with placebo. These effects began an average of 1.1 h after 10 µg LSD administration, peaked at 2.5 h, and ended at 5.1 h. The 20 µg dose of LSD significantly increased ratings of "under the influence," "good drug effects," and "bad drug effects." LSD concentrations dose-proportionally increased at doses as low as 5-20 µg and decreased with a half-life of 3 h. The threshold dose of LSD base for psychotropic effects was 10 µg.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion date, Trial primary completion date: LSD Therapy for Persons Suffering From Major Depression (clinicaltrials.gov) - Feb 9, 2021
P2, N=60, Recruiting,
However, changes within the DMN might explain antidepressants effects of some of these substances. Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment open: L-Ket: Effect of Ketanserin After LSD Administration (clinicaltrials.gov) - Oct 26, 2020
P1, N=24, Recruiting,
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| ketamine / Generic mfg., lysergic acid diethylamide (LSD) / Mindmed, University Hospital Basel, psilocybin (COMP360) / Compass Pathways
[VIRTUAL] Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers: Preliminary Findings () - Sep 30, 2020 - Abstract #ACNP2020ACNP_541;
This line of thinking is supported by recent findings with ketamine and ayahuasca (containing the psychedelic DMT) demonstrating increased serum BDNF levels respectively 24 and 48 hours after a single dose, compared to placebo, which was related to fast antidepressant actions. Besides emphasizing the need to sample BDNF beyond the elimination stage, in addition to including behavioral and/or imaging measures, future studies could focus on similarities between underlying biological pathways of the well-studied ketamine, and LSD, as it will contribute to understanding the scope of effects LSD, might have, based on ketamine findings.
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment open: LSD Therapy for Persons Suffering From Major Depression (clinicaltrials.gov) - Dec 3, 2019
P2, N=60, Recruiting,
Besides emphasizing the need to sample BDNF beyond the elimination stage, in addition to including behavioral and/or imaging measures, future studies could focus on similarities between underlying biological pathways of the well-studied ketamine, and LSD, as it will contribute to understanding the scope of effects LSD, might have, based on ketamine findings. Not yet recruiting --> Recruiting
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial initiation date: LSD Therapy for Persons Suffering From Major Depression (clinicaltrials.gov) - Sep 19, 2019
P2, N=60, Not yet recruiting,
Not yet recruiting --> Recruiting Initiation date: Aug 2019 --> Nov 2019
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment open: Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache (clinicaltrials.gov) - Jan 4, 2019
P2, N=30, Recruiting,
Trial completion date: Mar 2019 --> Jul 2019 | Trial primary completion date: Mar 2019 --> Jul 2019 Not yet recruiting --> Recruiting
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion, Trial primary completion date: Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing (clinicaltrials.gov) - Oct 15, 2018
P1, N=28, Completed,
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Aug 2018
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment closed: Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing (clinicaltrials.gov) - Aug 15, 2018
P1, N=24, Active, not recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Aug 2018 Recruiting --> Active, not recruiting
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Trial completion, Enrollment change, Trial primary completion date: Neuronal Correlates of Altered States of Consciousness (clinicaltrials.gov) - Sep 25, 2015
P0, N=24, Completed,
Not yet recruiting --> Recruiting Recruiting --> Completed | N=20 --> 24 | Trial primary completion date: Dec 2015 --> Sep 2015
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment open: Neuronal Correlates of Altered States of Consciousness (clinicaltrials.gov) - Jan 4, 2015
P0, N=20, Recruiting,
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| lysergic acid diethylamide (MM-120) / Mindmed, University Hospital Basel
Enrollment closed: Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study (clinicaltrials.gov) - Jan 22, 2014
P0, N=16, Active, not recruiting,
Trial primary completion date: Jul 2014 --> Feb 2014 Recruiting --> Active, not recruiting
|
